Prognostic factors for patients with heparin-induced thrombocytopenia: a systematic review

被引:3
作者
Colarossi, Giorgia [1 ]
Schnoering, Heike [1 ]
Trivellas, Andromahi [2 ]
Betsch, Marcel [3 ]
Hatam, Nima [1 ]
Eschweiler, Joerg [4 ]
Tingart, Markus [4 ]
Migliorini, Filippo [4 ]
机构
[1] RWTH Aachen Univ Clin, Dept Cardiac & Thorac Surg, Pauwelstr 31, D-52074 Aachen, Germany
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Orthopaed, Los Angeles, CA 90095 USA
[3] UTOSM, Womens Coll Hosp, Toronto, ON, Canada
[4] RWTH Aachen Univ Clin, Dept Orthopaed Surg, Pauwelstr 31, D-52074 Aachen, Germany
关键词
Heparin-induced thrombocytopenia; HIT; Prognostic factors; Systematic review; DIRECT THROMBIN INHIBITORS; ARGATROBAN ANTICOAGULATION; RECOMBINANT HIRUDIN; RISK-FACTORS; LEPIRUDIN; MANAGEMENT; THERAPY; BIVALIRUDIN; PROPHYLAXIS; PREVENTION;
D O I
10.1007/s11096-020-01166-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Little is known with regards to the prognostic factors for patients with suspected or diagnosed Heparin-Induced Thromobocytopenia (HIT). The role of patient and therapy characteristics may play a role in predicting the outcome.Aim of the reviewTo investigate the role of patient and therapy characteristics as potential prognostic factors for HIT-related complications (haemorrhagic and thromboembolic events), and mortality.MethodThe present systematic review was conducted according to the PRISMA statement. In September 2020, the main online databases were accessed: Pubmed, EMBASE, Scopus, Google Scholar. All the clinical trials concerning the management of patients with suspected or confirmed HIT were eligible. Studies evaluating the use of oral anticoagulants (e.g. vitamin K antagonists, Apixaban) were not considered, along with those comparing the use of heparin. For pairwise correlation, the Pearson Product-Moment Correlation Coefficient (r) was used. The final effect was evaluated according to the Cauchy-Schwarz inequality.ResultsData from 33 clinical studies (4338 patients) were retrieved. The overall mean age was 62.3 +/- 6.6 years old. Patients with HIT-related thromboembolism at the moment of diagnosis were associated with greater rate of haemorrhages (P > 0.0001), thromboembolism (P > 0.0001) and mortality (P = 0.001). Patients with more comorbidities at diagnosis were associated with a greater risk of haemorrhages (P = 0.07), thromboembolism (P = 0.002) and mortality (P = 0.002). Patients with longer duration of the therapy were associated with lower rate of mortality (P = 0.04).ConclusionsPatient comorbidities, presence of HIT-related thromboembolism on admission and shorter anticoagulant therapy were found to be negative prognostic factors. Thrombocythemia on admission, patients age and gender did not influence the overall outcome.
引用
收藏
页码:449 / 460
页数:12
相关论文
共 57 条
  • [1] Direct thrombin inhibitors for management of heparin-induced thrombocytopenia in patients receiving renal replacement therapy: Comparison of clinical outcomes
    Abel, Erik E.
    Kane-Gill, Sandra L.
    Seybert, Amy L.
    Kellum, John A.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (18) : 1559 - 1567
  • [2] Heparin induced thrombocytopenia: diagnosis and management update
    Ahmed, I.
    Majeed, A.
    Powell, R.
    [J]. POSTGRADUATE MEDICAL JOURNAL, 2007, 83 (983) : 575 - 582
  • [3] Heparin-induced thrombocytopenia
    Arepally, Gowthami M.
    Ortel, Thomas L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (08) : 809 - 817
  • [4] Comparison of bivalirudin to lepirudin and argatroban in patients with heparin-induced thrombocytopenia (Reprinted from Journal of Health-System Pharmacy Residents JHPR, vol 1, issue 4, 2013)
    Bain, Jonathan
    Meyer, Andrew
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (17) : S104 - S109
  • [5] Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients
    Bartholomew, John R.
    Pietrangeli, Carolynn E.
    Hursting, Marcie J.
    [J]. DRUGS & AGING, 2007, 24 (06) : 489 - 499
  • [6] Argatroban anticoagulation in critically ill patients
    Beiderlinden, Martin
    Treschan, Tanja A.
    Goerlinger, Klaus
    Peters, Juergen
    [J]. ANNALS OF PHARMACOTHERAPY, 2007, 41 (05) : 749 - 754
  • [7] Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial
    Beiderlinden, Martin
    Werner, Patrick
    Bahlmann, Astrid
    Kemper, Johann
    Brezina, Tobias
    Schaefer, Maximilian
    Goerlinger, Klaus
    Seidel, Holger
    Kienbaum, Peter
    Treschan, Tanja A.
    [J]. BMC ANESTHESIOLOGY, 2018, 18
  • [8] A Randomized, Open-Label Pilot Study Comparing Desirudin and Argatroban in Patients With Suspected Heparin-Induced Thrombocytopenia With or Without Thrombosis: PREVENT-HIT Study
    Boyce, Steven W.
    Bandyk, Dennis F.
    Bartholomew, John R.
    Frame, James N.
    Rice, Lawrence
    [J]. AMERICAN JOURNAL OF THERAPEUTICS, 2011, 18 (01) : 14 - 22
  • [9] Incidence and Outcomes of Heparin-Induced Thrombocytopenia in Patients Undergoing Vascular Surgery
    Chaudhry, Rabail
    Wegner, Robert
    Zaki, John F.
    Pednekar, Greesha
    Tse, Alex
    Kukreja, Naveen
    Grewal, Navneet
    Williams, George W.
    [J]. JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2017, 31 (05) : 1751 - 1757
  • [10] American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia
    Cuker, Adam
    Arepally, Gowthami M.
    Chong, Beng H.
    Cines, Douglas B.
    Greinacher, Andreas
    Gruel, Yves
    Linkins, Lori A.
    Rodner, Stephen B.
    Selleng, Sixten
    Warkentin, Theodore E.
    Wex, Ashleigh
    Mustafa, Reem A.
    Morgan, Rebecca L.
    Santesso, Nancy
    [J]. BLOOD ADVANCES, 2018, 2 (22) : 3360 - 3392